A Benefit-Risk Assessment of Inhaled Long-Acting β 2 -Agonists in the Management of Obstructive Pulmonary Disease

Author： Sovani Milind P. Whale Christopher I. Tattersfield Anne. E.

ISSN： 0114-5916

Source： Drug Safety, Vol.27, Iss.10, 2004-01, pp. : 689-715

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination Therapy of Inhaled Corticosteroids and Long-Acting &bgr;2- Adrenergics In Management of Patients with Chronic Obstructive Pulmonary Disease

Current Pharmaceutical Design, Vol. 10, Iss. 28, 2004-11 ,pp. : 3547-3560

Bentham Science Publishers

Access to resources Recommend Favorite

Long-Acting Agonists in the Management of Stable Chronic Obstructive Pulmonary Disease

By Cazzola M.

Drugs, Vol. 60, Iss. 2, 2000-08 ,pp. : 307-320

Adis International

Access to resources Recommend Favorite

Ultra long-acting β₂-agonists in development for asthma and chronic obstructive pulmonary disease

By Cazzola Mario Matera Maria Gabriella Lötvall Jan

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 7, 2005-07 ,pp. : 775-783

Informa Healthcare

Access to resources Recommend Favorite

Indacaterol: a new long-acting β₂-agonist in the management of chronic obstructive pulmonary disease

By Steiropoulos Paschalis Papanas Nikolaos Nena Evangelia Bouros Demosthenes

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1015-1029

Informa Healthcare

Access to resources Recommend Favorite

Long-acting β₂ agonists

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 1, 2006-01 ,pp. : 99-104

Informa Healthcare

Access to resources Recommend Favorite